Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Menadione Sulfurous Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 3/20 | 0.34 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.34 |
| ▸ | CA4 known ✓ | P22748 | 2/20 | 0.33 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.97 |
| ▸ | POLB | P06746 | 2/20 | 0.97 |
| ▸ | PARG | Q86W56 | 1/20 | 0.37 |
| ▸ | PKLR | P30613 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Menadione Sulfurous Acid SCHEMBL435171 | 1.00 | MEN1 (0.97) | MEN1KMT2APOLBPARGPKLR | |
| Menadione Sulfurous Acid SCHEMBL461612 | 0.98 | MEN1 (1.00) | MEN1KMT2APOLBPARGPKLR | |
| Menadione Sulfurous Acid SCHEMBL29364956 | 0.98 | MEN1 (1.00) | MEN1KMT2APOLBPARGPKLR | |
| Menadione Sulfurous Acid SCHEMBL460403 | 0.98 | MEN1 (1.00) | MEN1KMT2APOLBPARGPKLR | |
| Menadione Sulfurous Acid SCHEMBL459906 | 0.97 | MEN1 (0.91) | MEN1KMT2APOLBPARGPKLR | |
| Menadione Sulfurous Acid SCHEMBL461201 | 0.97 | MEN1 (0.91) | MEN1KMT2APOLBPARGPKLR | |
| SCHEMBL18309831 | 0.83 | MEN1 (0.69) | MEN1KMT2APOLBPARGALDH1A1 | |
| Menadione Sulfurous Acid SCHEMBL18314150 | 0.81 | POLB (0.67) | MEN1KMT2APOLBPARGALDH1A1 | |
| Menadione Sulfurous Acid SCHEMBL459525 | 0.81 | POLB (0.67) | MEN1KMT2APOLBPARGALDH1A1 | |
| Menadione Sulfurous Acid SCHEMBL459627 | 0.80 | POLB (0.65) | MEN1KMT2APOLBPARGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11998523-B2 | Ascorbic acid and quinone compounds for treating Chagas disease | IC-MedTech Corp. (US) | 2024-06-04 | — | — | US | claimed |
| CN-118831075-B | Compound medicine for delaying skeletal muscle aging and application thereof | 中国医科大学 | 2026-01-27 | — | — | CN | disclosed |
| EP-4582100-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | Toray Industries, Inc. (JP) | 2025-07-09 | — | — | EP | disclosed |
| CN-118831075-A | Compound medicine for delaying skeletal muscle aging and application thereof | 中国医科大学 | 2024-10-25 | — | — | CN | disclosed |
| CN-118831075-A | Compound medicine for delaying skeletal muscle aging and application thereof | 中国医科大学 | 2024-10-25 | — | — | CN | disclosed |
| WO-2024048541-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | 東レ株式会社 | 2024-03-07 | — | — | WO | disclosed |
| EP-3344063-B1 | METHODS OF INCREASING FAT SOLUBLE VITAMIN UPTAKE IN FEED | DUPONT NUTRITION BIOSCI APS (DK) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998523-B2 | Ascorbic acid and quinone compounds for treating Chagas disease | NQO1, ADH7, TALDO1 | CA1 1846/4885CA2 974/4885CA4 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.